Prelude Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Prelude Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.03M	Sell	13,807 -10,430	-43%	-$756K	0.08%	301
2025 Q4	$1.85M	Sell	24,237 -15,612	-39%	-$1.02M	0.14%	164
2025 Q3	$2.07M	Sell	39,849 -10,974	-22%	-$535K	0.16%	155
2025 Q2	$2.19M	Sell	50,823 -18	-0%	-$655	0.21%	123
2025 Q1	$1.76M	Sell	50,841 -17,859	-26%	-$602K	0.13%	171
2024 Q4	$1.89M	Buy	68,700 +7,550	+12%	+$195K	0.12%	199
2024 Q3	$1.56M	Buy	61,150 +37,839	+162%	+$993K	0.09%	275
2024 Q2	$590K	Buy	23,311 +11,797	+102%	+$323K	0.04%	470
2024 Q1	$356K	Sell	11,514 -3,740	-25%	-$127K	0.02%	808
2023 Q4	$616K	Buy	15,254 +40	+0.3%	+$1.2K	0.04%	432
2023 Q3	$401K	Sell	15,214 -3,827	-20%	-$109K	0.03%	545
2023 Q2	$328K	Buy	19,041 +3,764	+25%	+$56.6K	0.02%	602
2023 Q1	$253K	Sell	15,277 -8,124	-35%	-$94.7K	0.02%	732
2022 Q4	$178K	Buy	+23,401	New	+$224K	0.01%	997

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's BBIO Position: Q1 2026 in Review

Prelude Capital Management reduced its BridgeBio Pharma (BBIO) stake by 43% in Q1 2026, selling an estimated $756K and leaving 13,807 shares worth $1.03M. The position accounts for 0.08% of the portfolio, ranked #301.

Prelude Capital Management first reported a position in BBIO in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.19M in Q2 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Prelude Capital Management held 13,807 shares of BridgeBio Pharma worth $1.03M as of Q1 2026.
Prelude Capital Management sold 10,430 BridgeBio Pharma shares in Q1 2026, an estimated $756K.
BridgeBio Pharma made up 0.08% of Prelude Capital Management's portfolio in Q1 2026, its #301 holding.
Prelude Capital Management first reported a position in BridgeBio Pharma in Q4 2022 and has held it in 14 quarters since.
Prelude Capital Management's BridgeBio Pharma position peaked at $2.19M in Q2 2025.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.